NAT2 and chronic myelogenous leukemia, BCR-ABL1 positive: Research by Ouerhani et al., (2011) investigated the association between xenobiotic metabolizing gene polymorphisms and susceptibility to AML, CML, CLL, and ALL in the Tunisian population, and found that NAT2 polymorphisms do not influence either predisposition or prognosis in CML patients.